Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00803556 · ClinicalTrials.gov registry record · Phase 1

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

A Phase 1 study of Breast Cancer and Solid Tumor, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
2
Study locations

NCT00803556 is a Phase 1 study of Breast Cancer and Solid Tumor that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 29 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00803556, a Phase 1 study of Breast Cancer and Solid Tumor, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
2
Study locations

Study Summary

To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients with advanced solid tumor malignancies

Conditions Studied

Breast Cancer Solid Tumor

Interventions

  • DRUG Trastuzumab
  • DRUG Paclitaxel
  • DRUG Alvespimycin

Study Locations (2)

Indiana

  • Indiana University Melvin & Bren Simon Cancer Center - Indianapolis

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2006-01
Est. Completion 2009-08
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00803556

The ClinicalTrials.gov registry entry for NCT00803556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.

NCT00803556 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, New York.

Frequently Asked Questions

What is clinical trial NCT00803556 about?

NCT00803556 is a clinical study titled "Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy". To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients with advanced solid tumor malignancies

What is the current status of trial NCT00803556?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2006-01. Estimated completion is 2009-08.

What conditions does trial NCT00803556 study?

This clinical trial studies the following conditions: Breast Cancer, Solid Tumor.

What interventions are being tested in trial NCT00803556?

The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Alvespimycin (DRUG).

Who is sponsoring clinical trial NCT00803556?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00803556 being conducted?

This trial has 2 study locations across Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Solid Tumor

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.